Newron Pharmaceuticals S.p.A. | |
Stock Exchange | SIX Swiss Exchange |
EPS |
CHF0.97 |
Market Cap |
CHF113.32 M |
Shares Outstanding |
17.85 M |
Public Float |
13.99 M |
Address |
via Ludovico Ariosto 21 Bresso Milan 20091 Italy |
Employees | - |
Website | http://www.newron.com |
Updated | 07/08/2019 |
Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Its products include Xadago for Parkinson's disease; sarizotan for patients with Rett syndrome; and ralfinamide for patients with rare pain indications. The company was founded by Luca Benatti, Ruggero Fariello, and Patricia Salvati in 1999 and is headquartered in Bresso, Italy. |